Fast neutrons and misonidazole for malignant astrocytomas.
Twenty-five patients with biopsy proven malignant supratentorial astrocytomas were entered into a Phase I/II study of misonidazole combined with neutron radiation at Fermilab Neutron Therapy Facility (NTF) between August 1979 and April 1981. The main objectives were to determine tissue tolerance in terms of acute and late effects, and to estimate tumor clearance and survival rates. The total dose was 18.0 Gy given in weekly fractions of 3.0 Gy over 39 days. Four hours before each irradiation, 2.5 gm/m2 misonidazole was administered orally. Patients' ages ranged from 28-69 years. Karnofsky status for most patients was 80 or 90; the lowest grade was 60. The majority of patients had glioblastoma multiforms. Most were already on steroids prior to initiation of therapy. The median survival for the whole group was 12.0 months; 25% were alive at 18 months with some neurological compromise. The median survival remained unchanged for subgroups of patients with ages between 40-60 years and with Karnofsky performance status above 80. Among the 19 patients with glioblastoma multiforme, the median survival was 10 months. Acute toxicity was within tolerable limits. Details of toxicity and tissue analysis from post mortems and second craniotomy samples are presented.
Kurup
P D
PD
Pajak
T F
TF
Hendrickson
F R
FR
Nelson
J S
JS
Mansell
J
J
Cohen
L
L
Awschalom
M
M
Rosenberg
I
I
Ten Haken
R K
RK
D000328:Adult; D000368:Aged; D001254:Astrocytoma / Q000532:radiotherapy*; D001932:Brain Neoplasms / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D005260:Female; D005909:Glioblastoma / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D008920:Misonidazole / Q000008:administration & dosage*; D009502:Neutrons; D009593:Nitroimidazoles / Q000008:administration & dosage*
D009593:Nitroimidazoles; D008920:Misonidazole